REMEGEN CO. LTD YC 1 (REG) - Total Liabilities
Based on the latest financial reports, REMEGEN CO. LTD YC 1 (REG) has total liabilities worth €3.64 Billion EUR (≈ $4.25 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. For the complete balance sheet picture, see REG total asset value.
REMEGEN CO. LTD YC 1 - Total Liabilities Trend (2021–2025)
This chart illustrates how REMEGEN CO. LTD YC 1's total liabilities have evolved over time, based on quarterly financial data. See REG working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
REMEGEN CO. LTD YC 1 Competitors by Total Liabilities
The table below lists competitors of REMEGEN CO. LTD YC 1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Acuren Corporation
NYSE:TIC
|
USA | $2.20 Billion |
|
TMC the metals company Inc
NASDAQ:TMC
|
USA | $215.07 Million |
|
BHP Group Limited
LSE:BHP
|
UK | GBX60.59 Billion |
|
Lianhe Chemical Technology Co Ltd
SHE:002250
|
China | CN¥6.70 Billion |
|
Extreme Networks Inc
NASDAQ:EXTR
|
USA | $1.07 Billion |
|
Atul Limited
NSE:ATUL
|
India | Rs16.04 Billion |
|
Banco do Nordeste do Brasil S.A
SA:BNBR3
|
Brazil | R$55.66 Billion |
|
Lojas Renner S.A.
SA:LREN3
|
Brazil | R$8.74 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down REMEGEN CO. LTD YC 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. Check REG financial resilience to evaluate the company's liquid asset resilience ratio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how REMEGEN CO. LTD YC 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for REMEGEN CO. LTD YC 1 (2021–2025)
The table below shows the annual total liabilities of REMEGEN CO. LTD YC 1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €3.64 Billion ≈ $4.25 Billion |
+3.61% |
| 2024-12-31 | €3.51 Billion ≈ $4.11 Billion |
+67.98% |
| 2023-12-31 | €2.09 Billion ≈ $2.44 Billion |
+100.88% |
| 2022-12-31 | €1.04 Billion ≈ $1.22 Billion |
+46.03% |
| 2021-12-31 | €712.79 Million ≈ $833.32 Million |
-- |
About REMEGEN CO. LTD YC 1
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Ve… Read more